Innovative fatty acid proves highly effective and well tolerated in clinical trial

Scientists of the Institute of Translational Immunology at University Medical Center Mainz have co-developed a novel drug that could effectively treat non-alcoholic fatty liver inflammation: the modified omega-3 fatty acid icosabutate. In the ongoing phase 2b clinical trial „ICONA“, the positive results seem to be confirmed: The compound prevented inflammation and scarring of the liver. To date, there is no established therapy and no approved drug for non-alcoholic fatty liver inflammation.